Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials
Abstract
The development of biomarkers for Alzheimer's disease (AD) has allowed researchers to increase sample homogeneity and test candidate treatments earlier in the disease. The integration of biomarker “screening” criteria should be met with a parallel implementation of standardized methods to disclose biomarker testing results to research participants; however, the extent to which protocolized disclosure occurs in trials is unknown.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 14, 2023
- Source ID
- 10.1002/alz.13380
Entities
People
- Allyson Rosen
- Annalise Rahman‐filipiak
- Ayda Rostamzadeh
- Corey Bolton
- Ellen Wijsman
- For The Advisory Group On Risk Evidence Education In Dementia (agreed)
- Jennifer Lingler
- Joshua D. Grill
- Judith Heidebrink
- Lindsay Clark
- Nathaniel A. Chin
- Nicole R. Fowler
- Sarah Getz
Organizations
- Alzheimer's Association
- Geriatric Research Education and Clinical Center
- Indiana University
- National Institute on Aging
- National Institutes of Health
- Stanford University
- United States Department of Defense
- University of California, Irvine
- University of Cologne
- University of Miami
- University of Michigan
- University of Pittsburgh
- University of Washington
- University of Wisconsin–Madison
- Vanderbilt University